Latest Breaking News On - Canbridge pharma - Page 1 : comparemela.com

CANbridge is coming for the anti-C5 market. With access to Soliris and Ultomiris limited in parts of the world, CANbridge has taken a rival C5 inhibitor through a phase 1 study, teeing it up to start an early test of the efficacy of the molecule.

Gerry coxCanbridge pharmaAstrazeneca alexionWuxi biologicsCanbridge life sciencesWuxi biologicsRare diseasesClinical trial data